Mutations in GPAA1, encoding a GPI transamidase complex protein, cause developmental delay, epilepsy, cerebellar atrophy and osteopenia.
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Main text
Initially identified more than three decades ago 1 , glycophosphatidylinositol (GPI) anchor proteins (AP) are emerging as a structurally diverse group of membrane-bound glycoproteins with important roles in cellular processes such as embryogenesis, fertilization and neurogenesis. It is estimated that there are about 150 GPI-APs in the human proteome.
The attachment of a GPI anchor to a protein is a conserved posttranslational modification which occurs in the endoplasmic reticulum (ER) and requires at least twelve reactions.
Proteins bearing the GPI-anchor exit the ER and are shuttled to the Golgi where they undergo fatty acid modification before being transported to the plasma membrane. Crucial in the GPI biosynthetic pathway are a group of enzymes encoded by five genes (PIGK and 1b (II-1 and II-2 of family 1 in figure 1 ) with the frameshift mutation (c.981_993del) which introduces a stop codon at amino acid 428 (p.Gln327Hisfs*102). We observed a decrease in GPAA1 mRNA up to 50% in both fibroblasts and LCLs ( Figure 3A , B).
Similarly, individual 2 (II-2 of family 2 in figure 1 ) with the intronic splicing mutation c.1164+5C>T also has decreased mRNA expression of GPAA1 in LCLs ( Figure 3B ).
To assess whether these mutations could affect the level of GPI-AP found at the cell surface, we performed flow cytometry analysis on whole blood and LCLs of affected individuals from families 1, 2 and 4 (samples from families 3 and 5 were not available).
Our results show that all tested individuals have GPI-AP deficiency. As shown in Figure   3C , individuals 1a and 1b (II-1 and II-2 of family 1 in figure 1 ) and 2 (II-2 of family 2 in figure 1 ) from two families presented with lower level of total GPI-AP in granulocytes as measured by a decrease in fluorescence-labeled aerolysin (FLAER) staining, while lower levels of CD16 were observed only in individuals 2 (II-2 of family 2 in figure 1 ), 4a and 4b
(VII-1 and VII-2 of family 4 in figure 1 ). In all LCLs examined, cell surface staining also showed decreased FLAER abundance ( Figure 3D ). In addition, a moderate decrease in CD24 was observed in all individual cell lines ( Figure S5 ).
Since fresh blood samples were not available for the affected individuals in family 3, we also tested the effect of the mutations by transfecting plasmids encoding mutant cDNAs driven by a weak promoter with only TATA box in cells knocked-out for GPAA1. GPAA1-deficient HAP1 cells were generated by CRISPR-Cas9 targeting of the gene. We then cloned human GPAA1 isoform 1 from a Hep3B cDNA library, and ligated to generate Cterminal tagged wild-type and variant pME hGPAA1 HA, then generated by site-directed mutagenesis the different variants. The pME promoter is the SR promoter (SV40 early promoter + HTLV LTR, enhancer) 13 . We also subcloned the constructs in plasmids with an intermediate strength promoter (pTK using the herpes simplex virus thymidine kinase, or HSV-TK, promoter), and a weak promoter (pTA using the TATA box from the HSV-TK promoter). The pTA promoter activity is similar to that of a promoter-less plasmid. The promoter activities are estimated as pTA:pTK:pME = 1:60:6000.
These results show a decreased activity compared to the wild-type protein only for the p.Ser51Leu and the p.Ala389Pro variants ( Figure 4A ). In this overexpression experiment, the other variants (p.Trp176Ser and p.Leu291Pro) possibly have sufficient residual activities to provide a rescue. Similar results were obtained after transfection with plasmids encoding the cDNAs under the control of stronger promoters (see Figures S6 and S7 ).
Western blotting of cell lysates after transfection of cells with a strong promoter (pME)
indicates that the p.Ala389Pro variant, located in the second transmembrane domain, leads to protein instability ( Figure 4B ). This could possibly be due to inadequate incorporation of the protein into the ER membrane.
We also assessed GPI-AP abundance on the cell surface of skin fibroblasts derived from individuals 1a, 1b (II-1 and II-2 of family 1 in figure 1 ) and 2 (II-2 of family 2 in figure 1) using FLAER, CD73 and CD109 as GPI cell surface markers ( Figure S8 ). Since individuals 1a and individual 2 had a significant downregulation in CD109 and CD73, respectively, we carried out rescue assays of these GPI-APs on fibroblasts of these individuals using a GPAA1-encoding Lv105 lentiviral vector. As shown in Figure 5 , CD109 in individual 1a
fibroblasts was completely rescued, and a partial rescue of CD73 was observed in All the individuals we describe have normal plasma and/or serum alkaline phosphatase (ALP) levels (Table 1) , which can be perturbed in other GPI-AP-synthesis-related disorders. Previous data suggested that the elevated serum ALP observed in some GPIbiosynthesis defects could be explained by cleavage of the signal peptide and secretion of soluble ALP because of abnormal GPI structure. 36 Since GPAA1 is a component of the GPI transamidase complex, mutations in this gene leading to decreased activity might lead to a decrease in serum ALP. This was not observed in our cohort, perhaps because the remaining enzymatic activity is sufficient to maintain normal serum ALP. This hypothesis is supported by the fact that no individual with bi-allelic loss-of-function mutations was identified. With regards to the mechanism leading to osteopenia, perhaps decreased surface expression of ALP on osteoblasts affects its function and secondarily leads to the osteopenia seen in these individuals.
To date, GPI-transamidase subunits have been proposed to function as oncogenes in breast and bladder cancer [7] [8] [9] . In addition, GPAA1 mRNA was also found to be overexpressed, correlating with increased GPAA1 protein accumulation, in samples from individuals with colorectal cancer 10 . It is thought that an overexpression of GPIbiosynthesis genes might lead to increased uPAR (a GPI-anchored protein) which in turn can lead to increased invasiveness and growth of tumor cells 37 .
Limited therapies are available for GPI-AP deficiency. Since alkaline phosphatase is essential to allow pyridoxal-phosphate to pass through the blood-brain barrier and pyridoxine passes through the blood-brain barrier and is converted to pyridoxalphosphate, which is important for GABA synthesis, pyridoxine supplementation sometimes helps control the seizures in individuals with GPI-biosynthesis defects including some patients with PIGO and PIGV mutations 38; 39 . This potential treatment has not yet been tested in our cohort. Future studies of GPAA1 deficiency, such as in mouse models, could allow further pathophysiological studies to explore the cerebellar and bone manifestations, and explore therapeutic avenues.
In summary, we report biallelic mutations in GPAA1 in ten individuals presenting global developmental delay, hypotonia, early-onset seizurescerebellar atrophy., and osteopenia.
Moreover, with functional studies, we demonstrate that these individuals have low cell surface GPI-AP levels demonstrating that those mutations cause a defect in the biosynthesis of GPI anchored proteins. Thus, our work expands the group of GPIbiosynthesis disorders and contributes to the understanding of the role of the GPI transamidase complex in health and development.
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